TSO3 Inc

TSO3 — Investor Presentation (August 2016)

21 slides from TSO3's investor presentation, August 2016

  1. Slide 1: Creating the Improved Standard in Healthcare Sterile Reprocessing

    TSX:TOS Creating the Improved Standard in Healthcare Sterile Reprocessing™ Corporate Presentation August 2016

  2. Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures

    Important Cautions Regarding Forward Looking Statements and Other Disclosures TSX:TOS The statements in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts (including, without limitation, those regarding the timing

  3. Slide 3: TSO3 - Our Vision

    TSO3 - Our Vision TSX:TOS To Create the Improved Standard in Healthcare Sterile Reprocessing™ 3

  4. Slide 4: Where We Are From and Where We Are Going

    Where We Are From and Where We Are Going TSX:TOS 2016 • Record revenues 2009 - 2014 • Reworked products • Record assembly capacity • Introduced STERIZONE® 125L+ • US$21.3M in cash1 and VP4 Sterilizers • Extended FDA Claims for colonoscopes • Sterilizers sold and used in and other long flexible endos

  5. Slide 5: Purpose

    Purpose TSX:TOS A Sterile Device for Every Procedure 5

  6. Slide 6: Approach

    Approach T at, TSX:TOS | [Propet \ f Pr est\ nnovation landyai re __ aries... Sterilizer Devices to All Patients

  7. Slide 7: The Science – Patents Pending or Applied For

    The Science – 36 Patents or Pending or Applied For TSX:TOS 7

  8. Slide 8: Modernizing Healthcare Sterilization Technology

    Modernizing Healthcare Sterilization Technology TSX:TOS Old Technology TSO3 Technology Low Temperature Sterilization Low Temperature Sterilization • 20+ year-old core technology  The next generation industry technology • Operators must choose from several operating cycles  Simple Single Cycle Oper

  9. Slide 9: STERIZONE VP4 Sterilizer

    STERIZONE® VP4 Sterilizer TSX:TOS FDA-Cleared - Dual Sterilant, Low Temperature Sterilization System –With Multi-Channeled Flexible Scope Claim Advantages Dynamic Sterilant Delivery System™ • Single cycle – easy to use, error free cycle selection Proprietary Technology automatically adjusts the ster

  10. Slide 10: Multiple Large Target Markets

    Multiple Large Target Markets TSX:TOS Existing Low-Temp Sterilizer Market Now Possible: Endoscopy/GI Market • Fastest growing sterilization segment (9%–10% CAGR1) • Expanded opportunity to terminally sterilize far more of the 55m+ annual procedures in US4 • Total equipment replacement value: $4.5 bi

  11. Slide 11: Growing Demand for MIS & Endoscopy Procedures

    Growing Demand for MIS & Endoscopy Procedures TSX:TOS Aging Recovery Bed Increasing Number of Minimally Invasive Surgeries Population Time Reduction (MIS) & Endoscopies Aging Population Expected to Drive Growth in MIS Surgeries and Endoscopies2 >30 million MIS procedures annually in the U.S.1 85+ 

  12. Slide 12: The Problem: Endoscopes & Superbugs

    The Problem: Endoscopes & Superbugs TSX:TOS  SUPERBUG = Antimicrobial Resistant Bacteria  2 million+ Americans suffer from antibiotic- resistant bacteria annually – 23,000 die1  CRE is resistant to most available antibiotics - up to 50% of infected patients die2  CRE infections increasingly prev

  13. Slide 13: A Call For Action

    A Call For Action TSX:TOS “Despite reprocessing in accordance with US guidelines, viable  55+ million endoscopic microbes and biologic debris persisted in clinically used [GI] procedures annually1 endoscopes, suggesting current reprocessing guidelines are not sufficient to ensure successful deconta

  14. Slide 14: The Solution: FDA Clearance of Endoscope Claims

    The Solution: FDA Clearance of Endoscope Claims TSX:TOS FDA has cleared the STERIZONE® VP4  July 2016: FDA cleared expanded indications Sterilizer for the sterilization of multi- for use of STERIZONE® VP4 Sterilizer to include: channeled flexible endoscopes (with a maximum of four channels) having

  15. Slide 15: Commercialization

    Commercialization TSX:TOS “The STERIZONE® VP4 Sterilizer  Getinge Infection Control - exclusive global uniquely addresses an unmet global distributor to STERIZONE® VP4 Sterilizer need for cost effective, high throughput sterilization of complex medical devices  Global sales & service - over 3,000

  16. Slide 16: 1H 2016 Financial Highlights – USD

    1H 2016 Financial Highlights – USD TSX:TOS Quarterly Revenues  50 STERIZONE® VP4 Sterilizers sold driving (US$ Millions) Q1 + Q2: Sold total of 50 record revenues of $6.1M in 1H 2016 STERIZONE® VP4 Sterilizers to Getinge  Gross margin of 28-36%1, which indicates 3.1M $3.0M equipment margins and li

  17. Slide 17: Key Stats (TSX: TOS)

    Key Stats (TSX: TOS) All Dollars in USD, unless noted otherwise TSX:TOS Stock Price (7/27/16) CAD $3.73 Total Revenue (mrq) $3.0M Distributor (Getinge) 5-Year Sales Target 52 Week High-Low CAD $1.42-$3.82 Gross Profit (mrq) $0.8M Avg. Daily Vol. (3 mo.) 0.3M High-margin consumables and Net Loss (mrq

  18. Slide 18: TSO3 Key Takeaways

    TSO3 Key Takeaways TSX:TOS  Razor/Razorblade recurring revenue business model with proprietary captive consumables.  Industry changing technology that is selling now Global Distribution Partner  Dual sterilant  Dynamic Sterilant Delivery  Addressing multi-billion $ market opportunities  Tradit

  19. Slide 19: Contact Us

    Contact Us TSX:TOS Investor Relations TSO3 Inc. - Canada Liolios Group, Inc. 2505, avenue Dalton Ron Both, Senior Managing Director Tel (949) 574-3860 Québec, Québec TOS@liolios.com G1P 3S5 CANADA Renmark Financial Communications Inc. Tel (418) 651-0003 Barry Mire, Vice President info@tso3.com Tel (

  20. Slide 20: Appendix

    Appendix +,

  21. Slide 21: Regulatory Progression - Endoscopes

    Regulatory Progression - Endoscopes TSX:TOS FDA is considering an expansion of its sterilization requirements1,2 Body Reprocessing FDA Device Class Highest Contact Requirements Today Signaled Sterile Body Sterilization Critical Critical Margin Cavity of Safety Mucous High Level Semi-Critical Critica

TSO3 — Investor Presentation (August 2016) on 6ix